Hilliquin P, Natour J, Aissa J, Guinot P, Laoussadi S, Benveniste J, Menkes C J, Arnoux B
Service de Rhumatologie A, Hôpital Cochin, Paris, France.
Ann Rheum Dis. 1995 Feb;54(2):140-3. doi: 10.1136/ard.54.2.140.
To evaluate the role of platelet activating factor (PAF) in the early stage of arthritis.
Arthritis was induced in rabbits by weekly intra-articular injections of carrageenan. A PAF receptor antagonist, BN 50730, was used as a preventive or curative agent.
BN 50730 was able partially to prevent the development of arthritis, and was also active on established arthritis. The joint arthritis scores of BN treated animals were significantly lower than those of the non-treated animals. The blood concentrations of PAF, PAF bound to lipoproteins (lipo-PAF), and its precursor, lyso-PAF, were not correlated with clinical variations.
The present data demonstrate a therapeutic action of a PAF antagonist in experimental arthritis and suggest a critical role for PAF during the early stage of arthritis.
评估血小板活化因子（PAF）在关节炎早期的作用。
通过每周向兔关节腔内注射角叉菜胶诱导关节炎。使用PAF受体拮抗剂BN 50730作为预防或治疗药物。
BN 50730能够部分预防关节炎的发展，对已形成的关节炎也有作用。接受BN治疗的动物的关节关节炎评分显著低于未治疗的动物。PAF、与脂蛋白结合的PAF（脂蛋白-PAF）及其前体溶血-PAF的血药浓度与临床变化无关。
目前的数据证明了PAF拮抗剂在实验性关节炎中的治疗作用，并提示PAF在关节炎早期起关键作用。
